 PARIS and CAMBRIDGE, Mass., Feb. 17, 2021 GLOBE NEWSWIRE -- Biophytis SA NasdaqGS: BPTS; Euronext Growth Paris: ALBPS, a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces that patient recruitment will begin in France and Belgium for Part 2 of its COVA Study assessing Sarconeos BIO101 as a potential treatment for acute respiratory failure associated with COVID-19. 